{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:00:51Z","timestamp":1715986851673},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00108-018-0454-x","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T06:39:23Z","timestamp":1529563163000},"page":"674-680","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genetik von Schilddr\u00fcsenknoten und Schilddr\u00fcsenkarzinomen"],"prefix":"10.1007","volume":"59","author":[{"given":"D.","family":"F\u00fchrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"issue":"4","key":"454_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1210\/er.2004-0005","volume":"26","author":"K Krohn","year":"2005","unstructured":"Krohn K, F\u00fchrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26(4):504\u2013524","journal-title":"Endocr Rev"},{"issue":"29\u201330","key":"454_CR2","first-page":"506","volume":"109","author":"D F\u00fchrer","year":"2012","unstructured":"F\u00fchrer D, Bockisch A, Schmid KW (2012) Euthyroid goiter with and without nodules\u2014diagnosis and treatment. Dtsch Arztebl Int 109(29\u201330):506\u2013515","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"454_CR3","first-page":"411","volume":"16","author":"H Studer","year":"1995","unstructured":"Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia\u2014a changing concept: a\u00a0review focused on the thyroid gland. Endocr Rev 16(4):411\u2013426","journal-title":"Endocr Rev"},{"issue":"5","key":"454_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1210\/edrv.22.5.0444","volume":"22","author":"T Kimura","year":"2001","unstructured":"Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP (2001) Regulation of thyroid cell proliferation by TSH and other factors: a\u00a0critical evaluation of in vitro models. Endocr Rev 22(5):631\u2013656","journal-title":"Endocr Rev"},{"issue":"11","key":"454_CR5","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1210\/me.2011-0065","volume":"25","author":"K M\u00fcller","year":"2011","unstructured":"M\u00fcller K, F\u00fchrer D, Mittag J, Kl\u00f6ting N, Bl\u00fcher M, Weiss RE, Many MC, Schmid KW, Krohn K (2011) TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia. Mol Endocrinol 25(11):1867\u20131879","journal-title":"Mol Endocrinol"},{"issue":"5","key":"454_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00108-009-2500-1","volume":"51","author":"D F\u00fchrer","year":"2010","unstructured":"F\u00fchrer D, Schmid KW (2010) Benign thyroid nodule or thyroid cancer? Internist (Berl) 51(5):611\u2013619","journal-title":"Internist (Berl)"},{"issue":"10","key":"454_CR7","doi-asserted-by":"publisher","first-page":"E1645","DOI":"10.1210\/jc.2013-1266","volume":"98","author":"S Versteyhe","year":"2013","unstructured":"Versteyhe S, Driessens N, Ghaddhab C, Tarabichi M, Hoste C, Dumont JE, Miot F, Corvilain B, Detours V (2013) Comparative analysis of the thyrocytes and T cells: responses to H2O2 and radiation reveals an H2O2-induced antioxidant transcriptional program in thyrocytes. J\u00a0Clin Endocrinol Metab 98(10):E1645\u2013E1654","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"454_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/ERC-07-0283","volume":"16","author":"S Karger","year":"2009","unstructured":"Karger S, Weidinger C, Krause K, Sheu SY, Aigner T, Gimm O, Schmid KW, Dralle H, Fuhrer D (2009) FOXO3a: a\u00a0novel player in thyroid carcinogenesis? Endocr Relat Cancer 16(1):189\u2013199","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"454_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/JME-11-0119","volume":"48","author":"S Karger","year":"2012","unstructured":"Karger S, Krause K, Engelhardt C, Weidinger C, Gimm O, Dralle H, Sheu-Grabellus SY, Schmid KW, Fuhrer D (2012) Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumours. J\u00a0Mol Endocrinol 48(3):193\u2013202","journal-title":"J Mol Endocrinol"},{"issue":"16","key":"454_CR10","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1073\/pnas.1420707112","volume":"112","author":"R Ameziane-El-Hassani","year":"2015","unstructured":"Ameziane-El-Hassani R, Talbot M, de Souza Dos SMC, Al Ghuzlan A, Hartl D, Bidart JM, De Deken X, Miot F, Diallo I, de Vathaire F, Schlumberger M, Dupuy C (2015) NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc Natl Acad Sci USA 112(16):5051\u20135056. https:\/\/doi.org\/10.1073\/pnas.1420707112","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"454_CR11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/jcem.83.1.4477","volume":"83","author":"K Krohn","year":"1998","unstructured":"Krohn K, F\u00fchrer D, Holzapfel HP, Paschke R (1998) Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J\u00a0Clin Endocrinol Metab 83(1):130\u2013134","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"454_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2002-021020","volume":"88","author":"L Cheung","year":"2003","unstructured":"Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J\u00a0Clin Endocrinol Metab 88(1):354\u2013357","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"454_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1210\/er.2012-1072","volume":"34","author":"G Kleinau","year":"2013","unstructured":"Kleinau G, Neumann S, Gr\u00fcters A, Krude H, Biebermann H (2013) Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 34(5):691\u2013724","journal-title":"Endocr Rev"},{"issue":"11","key":"454_CR14","first-page":"3885","volume":"82","author":"D F\u00fchrer","year":"1997","unstructured":"F\u00fchrer D, Holzapfel HP, Wonerow P, Scherbaum WA, Paschke R (1997) Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J\u00a0Clin Endocrinol Metab 82(11):3885\u20133891","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"454_CR15","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1210\/jc.2002-021907","volume":"88","author":"MN Nikiforova","year":"2003","unstructured":"Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J\u00a0Clin Endocrinol Metab 88(5):2318\u20132326","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"454_CR16","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1016\/j.ajpath.2011.08.033","volume":"179","author":"K Krause","year":"2011","unstructured":"Krause K, Prawitt S, Eszlinger M, Ihling C, Sinz A, Schierle K, Gimm O, Dralle H, Steinert F, Sheu SY, Schmid KW, Fuhrer D (2011) Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma. Am J Pathol 179(6):3066\u20133074","journal-title":"Am J Pathol"},{"key":"454_CR17","volume-title":"Endokrinologie, Diabetologie und Stoffwechsel","author":"D F\u00fchrer","year":"2014","unstructured":"F\u00fchrer D, Gimm O, Brabant G, Rosenbaum-Krumme S, Schilddr\u00fcsenkarzinom SKW (2014) Rationelle Diagnostik und Therapie. In: Lehnert H (Hrsg) Endokrinologie, Diabetologie und Stoffwechsel, 3.\u00a0Aufl. Thieme, Stuttgart","edition":"3"},{"issue":"9","key":"454_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1055\/s-0043-109180","volume":"96","author":"D F\u00fchrer","year":"2017","unstructured":"F\u00fchrer D, Musholt T, Schmid KW (2017) Molekulare Pathogenese von Schilddr\u00fcsenknoten \u2013 Bedeutung f\u00fcr die klinische Versorgung. Laryngorhinootologie 96(9):590\u2013596","journal-title":"Laryngorhinootologie"},{"issue":"7","key":"454_CR19","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63(7):1454\u20131457","journal-title":"Cancer Res"},{"issue":"29","key":"454_CR20","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","volume":"22","author":"P Soares","year":"2003","unstructured":"Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, M\u00e1ximo V, Botelho T, Seruca R, Sobrinho-Sim\u00f5es M (2003) BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22(29):4578\u20134580","journal-title":"Oncogene"},{"issue":"5489","key":"454_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1126\/science.290.5489.138","volume":"290","author":"MN Nikiforova","year":"2000","unstructured":"Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE (2000) Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290(5489):138\u2013141","journal-title":"Science"},{"issue":"3","key":"454_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676\u2013690","journal-title":"Cell"},{"issue":"1","key":"454_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/thy.2014.0123","volume":"25","author":"GS Falchook","year":"2015","unstructured":"Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R (2015) BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71\u201377","journal-title":"Thyroid"},{"issue":"10","key":"454_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1089\/thy.2013.0057","volume":"23","author":"KB Kim","year":"2013","unstructured":"Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI (2013) Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23(10):1277\u20131283","journal-title":"Thyroid"},{"issue":"6","key":"454_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/CMR.0000000000000200","volume":"25","author":"R Dummer","year":"2015","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebb\u00e9 C, Hauschild A (2015) Integrating first-line treatment options into clinical practice: what\u2019s new in advanced melanoma? Melanoma Res 25(6):461\u2013469","journal-title":"Melanoma Res"},{"issue":"38","key":"454_CR26","doi-asserted-by":"crossref","first-page":"40418","DOI":"10.18632\/oncotarget.6340","volume":"6","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Yu J, Lee C, Xu B, Sartor MA, Koenig RJ (2015) Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein. Oncotarget 6(38):40418\u201340432","journal-title":"Oncotarget"},{"issue":"11","key":"454_CR27","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","volume":"69","author":"JC Ricarte-Filho","year":"2009","unstructured":"Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885\u20134893","journal-title":"Cancer Res"},{"key":"454_CR28","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","volume":"381","author":"M Xing","year":"2013","unstructured":"Xing M, Haugen BR, Schlumberger M (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381:1058\u20131069","journal-title":"Lancet"},{"issue":"3","key":"454_CR29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH et\u00a0al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J\u00a0Clin Invest 126(3):1052\u20131066. https:\/\/doi.org\/10.1172\/JCI85271","journal-title":"J Clin Invest"},{"issue":"42","key":"454_CR30","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1038\/onc.2013.446","volume":"33","author":"T Liu","year":"2014","unstructured":"Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J et al (2014) The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33(42):4978\u20134984","journal-title":"Oncogene"},{"issue":"4","key":"454_CR31","doi-asserted-by":"publisher","first-page":"E632","DOI":"10.1210\/jc.2014-3606","volume":"100","author":"X Shi","year":"2015","unstructured":"Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X et\u00a0al (2015) Association of TERT promoter mutation 1,295,228\u202fC\u3009T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J\u00a0Clin Endocrinol Metab 100(4):E632\u20137","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"454_CR32","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA et\u00a0al (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J\u00a0Clin Oncol 32(25):2718\u20132726","journal-title":"J Clin Oncol"},{"issue":"5","key":"454_CR33","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, M\u00e1ximo V, Sobrinho-Sim\u00f5es M, Soares P (2014) TERT promoter mutations are a\u00a0major indicator of poor outcome in differentiated thyroid carcinomas. J\u00a0Clin Endocrinol Metab 99(5):E754\u201365","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"454_CR34","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","volume":"24","author":"JW Kunstman","year":"2015","unstructured":"Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM et al (2015) Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 24(8):2318\u20132312","journal-title":"Hum Mol Genet"},{"issue":"3","key":"454_CR35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12020-016-1080-9","volume":"54","author":"S Latteyer","year":"2016","unstructured":"Latteyer S, Tiedje V, K\u00f6nig K, Ting S, Heukamp LC, Meder L, Schmid KW, F\u00fchrer D, Moeller LC (2016) Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 54(3):733\u2013741","journal-title":"Endocrine"},{"issue":"26","key":"454_CR36","doi-asserted-by":"publisher","first-page":"42613","DOI":"10.18632\/oncotarget.17300","volume":"8","author":"V Tiedje","year":"2017","unstructured":"Tiedje V, Ting S, Herold T, Synoracki S, Latteyer S, Moeller LC, Zwanziger D, Stuschke M, Fuehrer D, Schmid KW (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8(26):42613\u201342620","journal-title":"Oncotarget"},{"issue":"11","key":"454_CR37","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1073\/pnas.1321937111","volume":"111","author":"LM Kelly","year":"2014","unstructured":"Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, Gandhi M, Carty SE, Hodak SP, Luo J, Dacic S, Yu YP, Nikiforova MN, Ferris RL, Altschuler DL, Nikiforov YE (2014) Identification of the transforming STRN-ALK fusion as a\u00a0potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci USA 111(11):4233\u20134238","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"454_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1210\/jc.2014-2803","volume":"100","author":"N Smith","year":"2015","unstructured":"Smith N, Nucera C (2015) Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J\u00a0Clin Endocrinol Metab 100(1):35\u201342","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"454_CR39","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1158\/0008-5472.CAN-10-4041","volume":"71","author":"AK Murugan","year":"2011","unstructured":"Murugan AK, Xing M (2011) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71(13):4403\u20134411","journal-title":"Cancer Res"},{"issue":"3","key":"454_CR40","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-17-0435","volume":"25","author":"V Tiedje","year":"2018","unstructured":"Tiedje V, Stuschke M, Weber F, Dralle H, Moss L, F\u00fchrer D (2018) Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer 25(3):R153\u2013R161","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"454_CR41","first-page":"66","volume":"39","author":"V Tiedje","year":"2015","unstructured":"Tiedje V, Kroiss M, Dralle H, Ting S, Stuschke M, Flentje M, Bauer S, Weber F, Brabant G, Lorenz K, Fassnacht M, F\u00fchrer D, Schmid KW (2015) Protokoll zur multimodalen Therapie des anaplastischen Schilddr\u00fcsenkarzinoms. Endokrinol Inf 39(3):66\u201365","journal-title":"Endokrinol. Inf."},{"issue":"7","key":"454_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1056\/NEJMc1215697","volume":"368","author":"MH Rosove","year":"2013","unstructured":"Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N\u00a0Engl J Med 368(7):684\u2013685","journal-title":"N Engl J Med"},{"issue":"15","key":"454_CR43","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","volume":"371","author":"N Wagle","year":"2014","unstructured":"Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M et al (2014) Response and acquired resistance to everolimus in anaplastic thyroid cancer. N\u00a0Engl J Med 371(15):1426\u20131433","journal-title":"N Engl J Med"},{"issue":"20","key":"454_CR44","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","volume":"33","author":"Y Godbert","year":"2015","unstructured":"Godbert Y, Henriques de Figueiredo B, Bonichon F, Chibon F, Hostein I, Perot G et al (2015) Remarkable response to Crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. J\u00a0Clin Oncol 33(20):e84\u2013e87","journal-title":"J Clin Oncol"},{"issue":"10","key":"454_CR45","doi-asserted-by":"publisher","first-page":"R469","DOI":"10.1530\/ERC-16-0169","volume":"23","author":"S Latteyer","year":"2016","unstructured":"Latteyer S, Tiedje V, Schilling B, F\u00fchrer D (2016) Perspectives for immunotherapy in endocrine cancer. Endocr Relat Cancer 23(10):R469\u201384","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"454_CR46","doi-asserted-by":"publisher","first-page":"E364","DOI":"10.1210\/jc.2012-2703","volume":"98","author":"N Agrawal","year":"2013","unstructured":"Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW (2013) Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J\u00a0Clin Endocrinol Metab 98(2):E364\u2013E369","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"454_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-16-0252","volume":"175","author":"V Tiedje","year":"2016","unstructured":"Tiedje V, Ting S, Walter RF, Herold T, Worm K, Badziong J, Zwanziger D, Schmid KW, F\u00fchrer D (2016) Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. Eur J Endocrinol 175(3):173\u2013180","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"454_CR48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00108-014-3638-z","volume":"56","author":"V Tiedje","year":"2015","unstructured":"Tiedje V, Ting S, Dralle H, Schmid KW, F\u00fchrer D (2015) Medullary thyroid carcinoma. Internist (Berl) 56(9):1019\u20131031","journal-title":"Internist (Berl)"},{"issue":"6","key":"454_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00292-015-0035-x","volume":"36","author":"S Ting","year":"2015","unstructured":"Ting S, Schmid ST, Synoracki S, Schmid KW (2015) Thyroid C cells and their pathology: part 1: normal C cells,\u2014C cell hyperplasia,\u2014precursor of familial medullary thyroid carcinoma. Pathologe 36(6):571","journal-title":"Pathologe"},{"issue":"3","key":"454_CR50","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1210\/jc.2015-2948","volume":"101","author":"S Latteyer","year":"2016","unstructured":"Latteyer S, Klein-Hitpass L, Khandanpour C, Zwanziger D, Poeppel TD, Schmid KW, F\u00fchrer D, Moeller LC (2016) A 6\u2011base pair in frame germline deletion in Exon 7 of RET leads to increased RET phosphorylation, ERK activation, and MEN2A. J\u00a0Clin Endocrinol Metab 101(3):1016\u20131022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"454_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000346174","volume":"2012","author":"R Elisei","year":"2012","unstructured":"Elisei R, Alevizaki M, Conte-Devolx B et al (2012) European Thyroid Association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid\u00a0J 2012(1):216\u2013231","journal-title":"Eur Thyroid J"},{"issue":"6","key":"454_CR52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567\u2013610","journal-title":"Thyroid"},{"issue":"3","key":"454_CR53","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1210\/jc.2007-1714","volume":"93","author":"R Elisei","year":"2008","unstructured":"Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a\u00a010-year follow-up study. J\u00a0Clin Endocrinol Metab 93(3):682\u2013687","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0454-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0454-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0454-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T02:39:00Z","timestamp":1661481540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0454-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0454-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"21 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0F\u00fchrer gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}